Altimmune appoints former Dexcom CCO Teri Lawver and ex-Intercept CEO Jerry Durso to board

Altimmune, Inc.

Board expanded by two to ten; Lawver and Durso appointed effective Feb 24, 2025.
Lawver, former Dexcom EVP/CCO and J&J Worldwide VP Immunology, brings 30 years pharma/commercial experience.
Durso, ex-CEO of Intercept Pharmaceuticals and 22-year Sanofi vet, led rare liver disease franchise and acquisition.
Each director received initial option for 69,800 shares and $40,000 annual cash retainer.
Appointments support late-stage development and pre-commercial transition for pemvidutide.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jerome Durso

Director

ALT · Altimmune, Inc.

Effective: 2025-02-24
Filed: February 25, 2025, 6:59 PM ET

On February 24, 2025, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from eight to ten directors and appointed Teri Lawver and Jerome Durso as directors of the Board.

Appointed

Teri Lawver

Director

ALT · Altimmune, Inc.

Effective: 2025-02-24
Filed: February 25, 2025, 6:59 PM ET

On February 24, 2025, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from eight to ten directors and appointed Teri Lawver and Jerome Durso as directors of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jerome Durso was appointed as Director at Altimmune, Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 24, 2025, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from eight to ten directors and appointed Teri Lawver and Jerome Durso as directors of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Teri Lawver was appointed as Director at Altimmune, Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 24, 2025, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from eight to ten directors and appointed Teri Lawver and Jerome Durso as directors of the Board.

View on SEC.gov

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-25-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.